US equities |
TSLA $391.62 ▲+5.21% MU $903.70 ▲+2.98% META $630.56 ▼-1.88% NVDA $216.00 ▲+2.39% AAPL $343.91 ▼-1.10% SPCX $146.90 ▼-0.40% MSFT $532.60 ▲+1.54% AMD $531.28 ▲+2.80%
FinancialContent

Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares (NQ:LSE)

4.590 UNCHANGED
Delayed Quote Updated: 12:45 PM EDT, Oct 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung Cancer
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
Avacta Group plc: Faridoxorubicin Treatment Results in Near Doubling of Progression-Free Survival and Clinically Meaningful Tumor Shrinkage in Most Patients with Salivary Gland Cancers
From Avacta Group PLC
Via GlobeNewswire
News headline image
HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Highlights SAFFRON Global Phase III Data Presented at ESMO Congress 2026 and Simultaneously Published in The New England Journal of Medicine
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
Avacta Highlights pre|CISION® Platform Data and Ongoing FOCUS-01 Trial Design with FAP-Exd (AVA6103)
From Avacta Group PLC
Via GlobeNewswire
News headline image
HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
Seeing Machines launches Technical Paper demonstrating real-time 3D human understanding for Physical AI
Delivering up to 180 FPS on NVIDIA Jetson Thor, Seeing Machines HMR combines state-of-the-art accuracy with low latency and compact model size for embedded deployment 
From Seeing Machines
Via GlobeNewswire
News headline image
Avacta Group plc: Interim Results for the Six Months to June 30, 2026, and Business Update
From Avacta Group PLC
Via GlobeNewswire
News headline image
HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors
First-in-class KRAS-payload leveraging synchronized EGFR inhibition 
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
Avacta Group plc: The FOCUS-01 Clinical Trial Design and Preclinical Data Further Demonstrate the Potential of AVA6103 at AACR Conference on Pancreatic Cancer
From Avacta Group PLC
Via GlobeNewswire
News headline image
HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
The Elmet Group Secures Long-Term Tungsten Offtake Agreement with Tungsten West’s Hemerdon Mine
From The Elmet Group
Via GlobeNewswire
News headline image
Avacta Achieves Clinical Proof of Mechanism for the Next Generation of pre|CISION® Medicines with AVA6103 (FAP-Exd) in the Phase 1 FOCUS-01 Trial
From Avacta Group PLC
Via GlobeNewswire
News headline image
Avacta Appoints Mats Blom to the Board of Directors as Chair of Audit Committee
From Avacta Group PLC
Via GlobeNewswire
News headline image
PPHC Increases 2026 Interim Dividend to $0.117 Per Share
From Public Policy Holding Company, Inc.
Via GlobeNewswire
News headline image
HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China
Findings build on the established success of the global SAFFRON and China SACHI trials, extending the clinical value of the all-oral combination into the first-line setting 
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Announces NMPA Approval for ATLED® (Fanregratinib) for the Treatment of Patients with FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma
Novel, highly potent oral selective FGFR 1/2/3 inhibitor approved for patients with advanced FGFR2-altered intrahepatic cholangiocarcinoma in China 
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO®
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
Public Policy Holding Company, Inc. Announces Q2 2026 Financial Results
From Public Policy Holding Company, Inc.
Via GlobeNewswire
News headline image
TierPoint Launches Adapt DDoS Protection
Always-On, Low-Latency DDoS Protection Powered by Corero Technology 
From TierPoint
Via GlobeNewswire
News headline image
PPHC Acquires Florida Government Relations Firm
From Public Policy Holding Company, Inc.
Via GlobeNewswire
News headline image
HUTCHMED Reports 2026 Interim Results
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
PPHC to Report Second Quarter 2026 Financial Results and Present at Upcoming Investor Conference
From Public Policy Holding Company, Inc.
Via GlobeNewswire
News headline image
PPHC Strengthens Public Affairs Offering with Hire of Managing Director and Content Specialist
From Public Policy Holding Company, Inc.
Via GlobeNewswire
News headline image
Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors
From Avacta Group PLC
Via GlobeNewswire
News headline image
HUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET Amplification
First selective MET inhibitor approved for patients with MET-amplified advanced gastric cancer or gastroesophageal junction adenocarcinoma in China 
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
PPHC Announces Acquisition of Tancredi
PPHC, TrailRunner International expands international footprint for financial, corporate and litigation communications in EMEA 
From Public Policy Holding Company, Inc.
Via GlobeNewswire
News headline image
HUTCHMED to Announce 2026 Half-Year Financial Results
From HUTCHMED (China) Limited
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >